Medindia
To Take Care of Your Diabetes Click Here
Medindia » Drug News

Diabetes Drug Dapagliflozin Proves Effective in Kidney Disease Patients

by Colleen Fleiss on November 3, 2022 at 11:35 PM
Listen to this News

In patients with chronic kidney disease (CKD), dapagliflozin, a sodium-glucose cotransporter-2 inhibitor was not only effective from a clinical standpoint, but also from a cost standpoint.


The DAPA-CKD trial showed treatment with dapagliflozin and standard of care led to a slowing of decline in kidney function and a reduction in the incidence of kidney failure and risk of cardiovascular- or kidney-related death, compared with placebo and standard of care.

Effects of Dapagliflozin in Chronic Kidney Disease

In this latest analysis, Phil McEwan, PhD (Health Economics and Outcomes Research Ltd., Cardiff, UK) and his colleagues estimated the cost-effectiveness of dapagliflozin added to standard therapy, compared with standard therapy alone, based on the results of the DAPA-CKD trial and considered from a multinational European healthcare system perspective.

‘Dapagliflozin, an anti-diabetic drug was shown to be an efficacious treatment for CKD in the Dapagliflozin And Prevention of Adverse outcomes in CKD (DAPA-CKD) trial.’

Treatment with dapagliflozin was predicted to slow the progression of CKD to kidney failure, to reduce the incidence of adverse clinical outcomes including hospitalization for heart failure, and to increase life expectancy by 1.7 years. Delayed CKD progression to kidney failure and reduced incidence of hospitalization for heart failure provided important cost-offsets to the drug acquisition cost of dapagliflozin.

"Our results indicate that should patients with chronic kidney disease be treated with dapagliflozin at an early stage of disease, the rate of cardio-renal complications could be reduced leading to improved health-related quality of life in patients and significant benefits for healthcare systems in a cost-effective manner," said Dr. McEwan.

An accompanying editorial notes that the study adds to a plethora of work demonstrating the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in both diabetic and non-diabetic kidney disease.

Source: Eurekalert

View Non AMP Site | Back to top ↑